577 related articles for article (PubMed ID: 29046323)
1. European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas.
Raverot G; Burman P; McCormack A; Heaney A; Petersenn S; Popovic V; Trouillas J; Dekkers OM;
Eur J Endocrinol; 2018 Jan; 178(1):G1-G24. PubMed ID: 29046323
[TBL] [Abstract][Full Text] [Related]
2. Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016.
McCormack A; Dekkers OM; Petersenn S; Popovic V; Trouillas J; Raverot G; Burman P;
Eur J Endocrinol; 2018 Mar; 178(3):265-276. PubMed ID: 29330228
[TBL] [Abstract][Full Text] [Related]
3. Aggressive Pituitary Adenomas and Carcinomas.
Ilie MD; Jouanneau E; Raverot G
Endocrinol Metab Clin North Am; 2020 Sep; 49(3):505-515. PubMed ID: 32741485
[TBL] [Abstract][Full Text] [Related]
4. [Aggressive pituitary adenoma and pituitary carcinoma].
Tóth M
Orv Hetil; 2023 Jul; 164(30):1167-1175. PubMed ID: 37516994
[TBL] [Abstract][Full Text] [Related]
5. Pituitary carcinomas and aggressive pituitary tumours: merits and pitfalls of temozolomide treatment.
Raverot G; Castinetti F; Jouanneau E; Morange I; Figarella-Branger D; Dufour H; Trouillas J; Brue T
Clin Endocrinol (Oxf); 2012 Jun; 76(6):769-75. PubMed ID: 22404748
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of temozolomide in the treatment of aggressive pituitary neuroendocrine tumours in Spain.
Lamas C; Cámara R; Fajardo C; Remon-Ruiz P; Biagetti B; Guerrero-Pérez F; Araujo-Castro M; Mora M; Hanzu F; Iglesias P; García-Centeno R; Soto A
Front Endocrinol (Lausanne); 2023; 14():1204206. PubMed ID: 37720528
[TBL] [Abstract][Full Text] [Related]
7. Management of Aggressive Pituitary Tumors - A 2019 Update.
Petersenn S
Horm Metab Res; 2019 Dec; 51(12):755-764. PubMed ID: 31826270
[TBL] [Abstract][Full Text] [Related]
8. How and when to use temozolomide to treat aggressive pituitary tumours.
Whitelaw BC
Endocr Relat Cancer; 2019 Aug; 26(9):R545-R552. PubMed ID: 31311005
[TBL] [Abstract][Full Text] [Related]
9. Temozolomide treatment can improve overall survival in aggressive pituitary tumors and pituitary carcinomas.
Lasolle H; Cortet C; Castinetti F; Cloix L; Caron P; Delemer B; Desailloud R; Jublanc C; Lebrun-Frenay C; Sadoul JL; Taillandier L; Batisse-Lignier M; Bonnet F; Bourcigaux N; Bresson D; Chabre O; Chanson P; Garcia C; Haissaguerre M; Reznik Y; Borot S; Villa C; Vasiljevic A; Gaillard S; Jouanneau E; Assié G; Raverot G
Eur J Endocrinol; 2017 Jun; 176(6):769-777. PubMed ID: 28432119
[TBL] [Abstract][Full Text] [Related]
10. Aggressive pituitary tumours and pituitary carcinomas.
Raverot G; Ilie MD; Lasolle H; Amodru V; Trouillas J; Castinetti F; Brue T
Nat Rev Endocrinol; 2021 Nov; 17(11):671-684. PubMed ID: 34493834
[TBL] [Abstract][Full Text] [Related]
11. Temozolomide therapy in patients with aggressive pituitary adenomas or carcinomas.
Losa M; Bogazzi F; Cannavo S; Ceccato F; Curtò L; De Marinis L; Iacovazzo D; Lombardi G; Mantovani G; Mazza E; Minniti G; Nizzoli M; Reni M; Scaroni C
J Neurooncol; 2016 Feb; 126(3):519-25. PubMed ID: 26614517
[TBL] [Abstract][Full Text] [Related]
12. [Pituitary carcinomas and aggressive adenomas: an overview and new therapeutic options].
Maïza JC; Caron P
Ann Endocrinol (Paris); 2009 Sep; 70 Suppl 1():S12-9. PubMed ID: 19878763
[TBL] [Abstract][Full Text] [Related]
13. Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience.
Raverot G; Sturm N; de Fraipont F; Muller M; Salenave S; Caron P; Chabre O; Chanson P; Cortet-Rudelli C; Assaker R; Dufour H; Gaillard S; François P; Jouanneau E; Passagia JG; Bernier M; Cornélius A; Figarella-Branger D; Trouillas J; Borson-Chazot F; Brue T
J Clin Endocrinol Metab; 2010 Oct; 95(10):4592-9. PubMed ID: 20660056
[TBL] [Abstract][Full Text] [Related]
14. Aggressive pituitary adenomas--diagnosis and emerging treatments.
Di Ieva A; Rotondo F; Syro LV; Cusimano MD; Kovacs K
Nat Rev Endocrinol; 2014 Jul; 10(7):423-35. PubMed ID: 24821329
[TBL] [Abstract][Full Text] [Related]
15. Malignant transformation in non-functioning pituitary adenomas (pituitary carcinoma).
Lenders N; McCormack A
Pituitary; 2018 Apr; 21(2):217-229. PubMed ID: 29299820
[TBL] [Abstract][Full Text] [Related]
16. Temozolomide in aggressive pituitary tumours and pituitary carcinomas.
McCormack A
Best Pract Res Clin Endocrinol Metab; 2022 Dec; 36(6):101713. PubMed ID: 36274026
[TBL] [Abstract][Full Text] [Related]
17. Aggressive pituitary tumours and carcinomas: two sides of the same coin?
Trouillas J; Burman P; McCormack A; Petersenn S; Popovic V; Dekkers O; Raverot G
Eur J Endocrinol; 2018 Jun; 178(6):C7-C9. PubMed ID: 29588294
[TBL] [Abstract][Full Text] [Related]
18. Aggressive pituitary tumors.
Chatzellis E; Alexandraki KI; Androulakis II; Kaltsas G
Neuroendocrinology; 2015; 101(2):87-104. PubMed ID: 25571935
[TBL] [Abstract][Full Text] [Related]
19. Aggressive and malignant pituitary tumours: state-of-the-art.
Dworakowska D; Grossman AB
Endocr Relat Cancer; 2018 Nov; 25(11):R559–R575. PubMed ID: 30306782
[TBL] [Abstract][Full Text] [Related]
20. European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors.
Fassnacht M; Dekkers OM; Else T; Baudin E; Berruti A; de Krijger R; Haak HR; Mihai R; Assie G; Terzolo M
Eur J Endocrinol; 2018 Oct; 179(4):G1-G46. PubMed ID: 30299884
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
